Clinical Trial Update: Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

View source ↗

Summary

This clinical trial update shows that ravulizumab is being studied as early treatment for anti-AChR antibody-positive generalized myasthenia gravis and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis
• Myasthenia Gravis Anti-acetylcholine Receptor Antibody Positive

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Generalized Myasthenia Gravis, Anti-AChR Antibody Positive | Status: RECRUITING